Depression Clinical Trial
Official title:
Relief-Hybrid: A Behavioral Intervention for Depression and Chronic Pain in Primary Care
Verified date | March 2023 |
Source | Weill Medical College of Cornell University |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Chronic pain and depression frequently co-exist in late and mid-life and contribute to increased disability, high health care costs, psychiatric comorbidity, and suicide. Older and middle-aged depressed-pain patients: a) are mainly treated in primary care practices; and b) are often prescribed medication, which increases the risk for addiction to opioids and benzodiazepines. Despite the need and desire by the patients and providers for primary care behavioral intervention, behavioral interventions are scarce in primary care. To address this need, Relief-Hybrid was created. Subjects are randomized to either the Relief-Hybrid intervention or to Referral to Mental Health/Usual Care. Subjects in both arms will complete research assessments at 6, 9, and 12 weeks. Subjects in the Relief-Hybrid arm will receive 5 weekly sessions with the study therapist (licensed social workers, LCSWs) and 4 self-administered, mobile technology-assisted sessions.
Status | Withdrawn |
Enrollment | 0 |
Est. completion date | December 2024 |
Est. primary completion date | December 2023 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 50 Years and older |
Eligibility | Inclusion Criteria: - 50 years or older - PHQ-9 score greater or equal to 10 - Chronic pain (non-cancer related, most days over the past 3 months) - Capacity to consent Exclusion Criteria: - DSM-5 Axis 1 diagnoses other than depression and anxiety disorders - Montreal Cognitive Assessment (MoCA) < 24 - Active suicidal ideation (MADRS item #10 greater or equal to 4 - Severe or life-threatening medical illness - Patients on psychotropics, opioids or benzodiazepines will be included if they do not meet DSM-5 criteria for opioid, anxiolytics or other substance abuse disorders |
Country | Name | City | State |
---|---|---|---|
United States | Iris Cantor Men's and Women's Health Centers | New York | New York |
United States | Irving Sherwood Wright Center | New York | New York |
United States | Weill Cornell Internal Medical Associates (WCIMA) | New York | New York |
United States | Weill Cornell Institute of Geriatric Psychiatry, Weill Cornell Medicine | White Plains | New York |
Lead Sponsor | Collaborator |
---|---|
Weill Medical College of Cornell University | National Institute of Mental Health (NIMH) |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change in depression symptoms, as measured by the Montgomery Asberg Depression Rating Scale (MADRS) | The MADRS is a 10 item questionnaire assessing severity of depression by scoring participants on mood, anxiety, sleep, concentration, appetite, and suicidal thoughts. The lowest score is 0, no depression symptoms, and the highest possible score is 60, severe depression symptoms. | Baseline, 6, 9, and 12 weeks | |
Primary | Change in Pain-Related Disability, as measured by the Roland-Morris Disability Questionnaire (RMDQ) | The RMDQ includes a scale assessing how much pain the participant has experienced in the past week, with 0 meaning no pain and 10 meaning pain as bad as he/she can imagine.
The RMDQ also includes a series of questions related to pain disability, with 0 indicating no pain-related disability, and 24 indicating severe pain-related disability. |
Baseline, 6, 9, and 12 weeks | |
Primary | Change in Mood, as measured by the Daily Photographic Affect Meter (PAM) | The PAM is used for assessing mood and emotional state. Participants can either score a "positive" or "negative" affect value. | Daily for 12 Weeks | |
Secondary | Interoceptive Awareness, as measured by the Multidimensional Assessment of Interoceptive Awareness (MAIA) | This assessment contains 32 questions measuring 8 areas of manifestations of emotions, including noticing, not-distracting, not-worrying, attention regulation, emotional awareness, self-regulation, body listening, and trusting. The scores for the questions associated with each of the 8 domains are averaged, with a score of 0 indicating "Never" and a score of 5 indicating "Always" | Baseline, 6, 9, and 12 weeks | |
Secondary | Affect, as measured by the Positive and Negative Affect Schedule (PANAS). | This scale consists of a series of 60 words and phrases and participants rate to what extent they have felt that way in the past week. The words are separated into 13 areas: general negative affect, fear, sadness, guilt, hostility, shyness, fatigue, general positive affect, joviality, self-assurance, attentiveness, serenity, and surprise. The scores range from 1 (very slightly/not at all), to 5 (extremely) for each word and each area is summed for the final score. | Baseline, 6, 9, and 12 weeks | |
Secondary | Mood, as measured by the Mood Likert Scale | This scale rates current sadness, ranging from 0 (not sad) to 10 (most sad). It also rates interest or pleasure in doing things, ranging from 0 (no interest or pleasure) to 10 (greatest interest or pleasure). | Daily for 12 weeks | |
Secondary | Pain, as measured by the Pain Likert Scale | This scale rates current pain, ranging from 0 (no pain) to 10 (worst pain possible). | Daily for 12 weeks | |
Secondary | Stress, as measured by the Stress Likert Scale | This scale rates current stress, ranging from 0 (no stress at all) to 10 (great stress). | Daily for 12 weeks | |
Secondary | Activities Monitoring | Activities monitoring through a phone application; measuring distance covered daily by the participant during the week. | Daily for 12 Weeks | |
Secondary | Activities Monitoring | Activities monitoring through a phone application; measuring number of places visited daily during the week. | Daily for 12 Weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT05777044 -
The Effect of Hatha Yoga on Mental Health
|
N/A | |
Recruiting |
NCT04977232 -
Adjunctive Game Intervention for Anhedonia in MDD Patients
|
N/A | |
Recruiting |
NCT04680611 -
Severe Asthma, MepolizumaB and Affect: SAMBA Study
|
||
Recruiting |
NCT04043052 -
Mobile Technologies and Post-stroke Depression
|
N/A | |
Completed |
NCT04512768 -
Treating Comorbid Insomnia in Transdiagnostic Internet-Delivered Cognitive Behaviour Therapy
|
N/A | |
Recruiting |
NCT03207828 -
Testing Interventions for Patients With Fibromyalgia and Depression
|
N/A | |
Completed |
NCT04617015 -
Defining and Treating Depression-related Asthma
|
Early Phase 1 | |
Recruiting |
NCT06011681 -
The Rapid Diagnosis of MCI and Depression in Patients Ages 60 and Over
|
||
Completed |
NCT04476446 -
An Expanded Access Protocol for Esketamine Treatment in Participants With Treatment Resistant Depression (TRD) Who do Not Have Other Treatment Alternatives
|
Phase 3 | |
Recruiting |
NCT02783430 -
Evaluation of the Initial Prescription of Ketamine and Milnacipran in Depression in Patients With a Progressive Disease
|
Phase 2/Phase 3 | |
Recruiting |
NCT05563805 -
Exploring Virtual Reality Adventure Training Exergaming
|
N/A | |
Completed |
NCT04598165 -
Mobile WACh NEO: Mobile Solutions for Neonatal Health and Maternal Support
|
N/A | |
Completed |
NCT03457714 -
Guided Internet Delivered Cognitive-Behaviour Therapy for Persons With Spinal Cord Injury: A Feasibility Trial
|
||
Recruiting |
NCT05956912 -
Implementing Group Metacognitive Therapy in Cardiac Rehabilitation Services (PATHWAY-Beacons)
|
||
Completed |
NCT05588622 -
Meru Health Program for Cancer Patients With Depression and Anxiety
|
N/A | |
Recruiting |
NCT05234476 -
Behavioral Activation Plus Savoring for University Students
|
N/A | |
Active, not recruiting |
NCT05006976 -
A Naturalistic Trial of Nudging Clinicians in the Norwegian Sickness Absence Clinic. The NSAC Nudge Study
|
N/A | |
Enrolling by invitation |
NCT03276585 -
Night in Japan Home Sleep Monitoring Study
|
||
Terminated |
NCT03275571 -
HIV, Computerized Depression Therapy & Cognition
|
N/A | |
Completed |
NCT03167372 -
Pilot Comparison of N-of-1 Trials of Light Therapy
|
N/A |